PMID- 36585731 OWN - NLM STAT- MEDLINE DCOM- 20230103 LR - 20230508 IS - 1748-717X (Electronic) IS - 1748-717X (Linking) VI - 17 IP - 1 DP - 2022 Dec 30 TI - Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study. PG - 218 LID - 10.1186/s13014-022-02190-4 [doi] LID - 218 AB - BACKGROUND AND PURPOSE: We evaluated and compared the efficacy and safety of chemotherapy with paclitaxel plus cisplatin (TP) or carboplatin (TC) in patients with locally advanced esophageal squamous cell carcinoma (LA-ESCC) who underwent neoadjuvant chemoradiotherapy (NCRT). MATERIALS AND METHODS: This single-center retrospective study assessed patients with LA-ESCC (cT2N + M0, cT3-4aNanyM0) receiving NCRT plus curative-intent esophagectomy with TP or TC regimen. The primary endpoints were grade >/= 3 adverse events (AEs) and overall survival (OS). AEs were compared using a t-test according to CTCAE 4.0. The Kaplan-Meier survival curves were compared using the log-rank test; the treatment effect was measured using hazard ratios and 95% confidence intervals. RESULTS: We included 151 and 50 patients in the TC and TP groups, respectively. Baseline demographic and clinical characteristics were well balanced between groups. The TP group exhibited significantly higher hematologic and non-hematologic AEs than the TC group, and the noticeable difference was the incidence of febrile neutropenia of grade 3 or higher (P = 0.011). No significant intergroup differences were noted considering postoperative complications, resection margins, or pathological complete remission rate (all P > 0.05). OS and progression-free survival (PFS) did not significantly differ between groups. The estimated 3-year OS and PFS rates were 65.1% versus 69.4% and 58.4% versus 53.5% for TP and TC groups, respectively. CONCLUSION: In patients with LA-ESCC, we recommend TC, not TP, as an optimal chemotherapy regimen for NCRT, given its superiorsafety profile and comparable efficacy. CI - (c) 2022. The Author(s). FAU - Jiang, Li AU - Jiang L AD - School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. AD - Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 55 South Renmin Ave, Fourth Section, Chengdu, 610041, Sichuan, China. FAU - Zhu, Jie AU - Zhu J AD - Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 55 South Renmin Ave, Fourth Section, Chengdu, 610041, Sichuan, China. FAU - Chen, Xue AU - Chen X AD - School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. AD - Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 55 South Renmin Ave, Fourth Section, Chengdu, 610041, Sichuan, China. FAU - Wang, Yi AU - Wang Y AD - Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 55 South Renmin Ave, Fourth Section, Chengdu, 610041, Sichuan, China. FAU - Wu, Lei AU - Wu L AD - Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 55 South Renmin Ave, Fourth Section, Chengdu, 610041, Sichuan, China. FAU - Wan, Gang AU - Wan G AD - Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 55 South Renmin Ave, Fourth Section, Chengdu, 610041, Sichuan, China. FAU - Han, Yongtao AU - Han Y AD - Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. FAU - Leng, Xuefeng AU - Leng X AD - Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. FAU - Peng, Lin AU - Peng L AD - Department of Thoracic Surgery, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, Chengdu, China. penglinms@126.com. FAU - Wang, Qifeng AU - Wang Q AD - Department of Radiation Oncology, Radiation Oncology Key Laboratory of Sichuan Province, Sichuan Cancer Hospital & Institute, Sichuan Cancer Center, School of Medicine, University of Electronic Science and Technology of China, 55 South Renmin Ave, Fourth Section, Chengdu, 610041, Sichuan, China. littlecancer@163.com. LA - eng PT - Journal Article DEP - 20221230 PL - England TA - Radiat Oncol JT - Radiation oncology (London, England) JID - 101265111 RN - Q20Q21Q62J (Cisplatin) RN - BG3F62OND5 (Carboplatin) RN - P88XT4IS4D (Paclitaxel) SB - IM EIN - Radiat Oncol. 2023 May 5;18(1):75. PMID: 37147731 MH - Humans MH - Cisplatin MH - *Esophageal Neoplasms MH - Carboplatin MH - Retrospective Studies MH - *Esophageal Squamous Cell Carcinoma/drug therapy MH - Neoadjuvant Therapy MH - *Carcinoma, Squamous Cell MH - Paclitaxel MH - Chemoradiotherapy MH - Antineoplastic Combined Chemotherapy Protocols/adverse effects PMC - PMC9801619 OTO - NOTNLM OT - Adverse effects OT - Carboplatin OT - Cisplatin OT - Esophageal squamous cell carcinoma OT - Locally advanced esophageal squamous cell carcinoma OT - Neoadjuvant chemoradiotherapy OT - Overall survival OT - Paclitaxel OT - Progression-free survival COIS- The authors declare no confict of interest. EDAT- 2022/12/31 06:00 MHDA- 2023/01/04 06:00 PMCR- 2022/12/30 CRDT- 2022/12/30 23:52 PHST- 2022/09/19 00:00 [received] PHST- 2022/12/26 00:00 [accepted] PHST- 2022/12/30 23:52 [entrez] PHST- 2022/12/31 06:00 [pubmed] PHST- 2023/01/04 06:00 [medline] PHST- 2022/12/30 00:00 [pmc-release] AID - 10.1186/s13014-022-02190-4 [pii] AID - 2190 [pii] AID - 10.1186/s13014-022-02190-4 [doi] PST - epublish SO - Radiat Oncol. 2022 Dec 30;17(1):218. doi: 10.1186/s13014-022-02190-4.